Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

Sameer Salunkhe

Contact

210-567-3767

salunkhe@uthscsa.edu

Departments & Divisions

Institutes & Centers

Research

Research profile

Sameer Salunkhe, Ph.D.

Assistant Professor/Research

Currently not seeking mentees

Dr. Salunkhe earned his Ph.D. in Cancer Cell Biology from ACTREC in Mumbai, India, and joined Dr. Sung's lab at UT Health San Antonio in 2019 as a postdoctoral fellow. Trained in DNA repair, cell biology, and biochemistry, Dr. Salunkhe’s research has been instrumental in advancing understanding of the biological and tumor-suppressing functions of the BRCA1-BARD1 complex and the 53BP1 ensemble. DNA end resection is a crucial step in homologous recombination repair, yet its regulatory mechanisms remain poorly understood. Utilizing his expertise in biochemically reconstituting critical DNA lesion-processing reactions, Dr. Salunkhe has provided mechanistic insights into how BRCA1-BARD1 directly enhances the efficiency of these processes. Dr. Salunkhe has also developed innovative methods for expressing and purifying essential proteins, including 53BP1, RIF1, and PTIP. His current research aims to elucidate the role of the 53BP1 ensemble in regulating DNA end resection.

  • Professional Background

    Education

    • 2018 - Ph.D. - Cancer Biology - Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) affiliated under Homi Bhabha National Institute (HBNI)

    Training

    • 2024 - Research Scientist Sr. - Biochemistry - UT Heath Science Center, San Antonio, TX, USA
    • 2019 - Postdoctoral fellow - Biochemistry - UT Heath Science Center, San Antonio, TX, USA

  • Research & Grants

    Research profile

  • Service

    Service to the Profession

    Ad hoc manuscript reviewer or other reviewer:

    Dates: 2023-Present, Entity Name: Journal of Biological Chemistry (JBC), Role: Reviewer, Frequency: Regular

    Dates: 2024-Present, Entity Name: Nucleic acid research (NAR), Role: Reviewer, Frequency: Standing member

    Dates: 2023-Present, Entity Name: Applied Biochemistry and Biotechnology, Role: Reviewer, Frequency: Standing member

  • Publications

       

      1. Mittra I, Samant U, Sharma S, Raghuram GV, Saha T, Tidke P, Pancholi N, Gupta D, Prasannan P, Gaikwad A, Salunkhe S. Cell-free chromatin from dying cancer cells integrate into genomes of bystander healthy cells to induce DNA damage and inflammation. Cell Death Discovery. 2017;3(1):1-14.

       

      1. Godbole M, Togar T, Patel K, Dharavath B, Yadav N, Janjuha S, Gardi N, Tiwary K, Terwadkar P, Desai S, Salunkhe S. Up-regulation of the kinase gene SGK1 by progesterone activates the AP-1–NDRG1 axis in both PR-positive and-negative breast cancer cells. Journal of Biological Chemistry. 2018;293(50):19263-76.

       

      1. Rajendra J, Datta KK, Farooqee SBUD, Thorat R, Kumar K, Gardi N, Kaur E, Nair J, Salunkhe S, Patkar K. Enhanced proteasomal activity is essential for long term survival and recurrence of innately radiation resistant residual glioblastoma cells. Oncotarget. 2018;9(45):27667.

       

      1. Salunkhe S, Mishra SV, Nair J, Ghosh S, Choudhary N, Kaur E, Shah S, Patkar K, Anand D, Khattry N. Inhibition of novel GCN5–ATM axis restricts the onset of acquired drug resistance in leukemia. International journal of cancer. 2018;142(10):2175-85.

       

      1. Iyer P, Shrikhande SV, Ranjan M, Joshi A, Gardi N, Prasad R, Dharavath B, Thorat R, Salunkhe S, Sahoo B. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early-stage gallbladder cancer. International journal of cancer. 2019;144(8):2008-19.

       

      1. Kaur E, Goda JS, Ghorai A, Salunkhe S, Shetty P, Moiyadi AV, Sridhar E, Mahajan A, Jalali R, Dutt S. Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome-a short report. Cellular oncology. 2019;42:107-16.

       

      1. Kaur E, Nair J, Ghorai A, Mishra SV, Achareker A, Ketkar M, Sarkar D, Salunkhe S, Rajendra J, Gardi N. Inhibition of SETMAR–H3K36me2–NHEJ repair axis in residual disease cells prevents glioblastoma recurrence. Neuro-oncology. 2020;22(12):1785-96.

       

      1. Salunkhe S, Chandran N, Chandrani P, Dutt A, Dutt S. CytoPred: 7-gene pair metric for AML cytogenetic risk prediction. Briefings in Bioinformatics. 2020;21(1):348-54.

       

      1. Salunkhe S, Mishra SV, Ghorai A, Hole A, Chandrani P, Dutt A, Chilakapati M, Dutt S. Metabolic rewiring in drug resistant cells exhibit higher OXPHOS and fatty acids as preferred major source to cellular energetics. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2020;1861(12):148300.

       

      1. Salunkhe S, Mishra SV, Nair J, Shah S, Gardi N, Thorat R, Sarkar D, Rajendra J, Kaur E, Dutt S. Nuclear localization of p65 reverses therapy-induced senescence. Journal of cell science. 2021;134(6):jcs253203.

       

      1. Xue C, Salunkhe SJ, Tomimatsu N, Kawale AS, Kwon Y, Burma S, Sung P, Greene EC. Bloom helicase mediates formation of large single–stranded DNA loops during DNA end processing. Nature communications. 2022;13(1):2248.

       

      1. Salunkhe S, Daley JM, Kaur H, Tomimatsu N, Xue C, Raina VB, Jasper AM, Rogers CM, Li W, Zhou S. Promotion of DNA end resection by BRCA1–BARD1 in homologous recombination. Nature. 2024:1-10.

       

       

      Original Peer-Reviewed Articles in Press or in Revision for Press: 

       

      1. Cody M. Rogers, Hardeep Kaur, Michelle L. Swift, Shuo Zhou, Ajinkya S. Kawale, Shahrez Syed, Korilynn G. Kelly, Angela M. Jasper, Salunkhe, S., et al. (2024) CTC1-STN1-TEN1 Restricts DNA End Resection in Homologous Recombination. (revision in Science)